Advisors Llc Orbi Med Capit... Net Worth

The estimated Net Worth of Advisors Llc Orbi Med Capit... is at least $50.8 Millón dollars as of 27 June 2023. Advisors Capit owns over 1,192,577 units of Imara Inc stock worth over $50,774,880 and over the last 6 years Advisors sold IMRA stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Advisors Capit IMRA stock SEC Form 4 insiders trading

Advisors has made over 8 trades of the Imara Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Advisors bought 1,192,577 units of IMRA stock worth $1,001,765 on 27 June 2023.

The largest trade Advisors's ever made was buying 1,363,636 units of Imara Inc stock on 11 December 2018 worth over $14,999,996. On average, Advisors trades about 634,927 units every 207 days since 2018. As of 27 June 2023 Advisors still owns at least 8,034,000 units of Imara Inc stock.

You can see the complete history of Advisors Capit stock trades at the bottom of the page.

What's Advisors Capit's mailing address?

Advisors's mailing address filed with the SEC is 601 LEXINGTON AVENUE601 LEXINGTON AVENUE, 54TH FLOOR54TH FLOOR, NEW YORKNEW YORK, NYNY, 1002210022.

Insiders trading at Imara Inc

Over the last 5 years, insiders at Imara Inc have traded over $7,889,059 worth of Imara Inc stock and bought 11,496,717 units worth $107,874,489 . The most active insiders traders include David M Mott, Lundbeck A S H y Capital Management, L.P.Ra .... On average, Imara Inc executives and independent directors trade stock every 23 days with the average trade being worth of $1,965,179. The most recent stock trade was executed by Michael Gray on 22 February 2023, trading 9,856 units of IMRA stock currently worth $46,028.

What does Imara Inc do?

Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia.

Complete history of Advisors Capit stock trades at Passage Bio Inc y Imara Inc

Imara Inc executives and stock owners

Imara Inc executives and other stock owners filed with the SEC include:

• Rahul D. Ballal,
  Chief Executive Officer
• Edward R. Conner,
  Director
• Enterprise Associates 14, L...,
  
• Springs Capital Management ...,
  
• Lundbeck A S H,
  10% owner
• City Capital Llc Bay City C...,
  
• Venture Investments, Llc Al...,
  10% owner
• Invest A/S Lundbeckfond,
  10% owner
• Bioscience Plc Arix Bioscie...,
  
• Capital Management, L.P.Ra ...,
  
• Advisors Llc Orbi Med Capit...,
  
• James G Mc Arthur,
  Director
• Carlbay City Capital Llc Ba...,
  
• Mette Kirstine Agger,
  Director
• David P Bonita,
  Director
• Barbara Dalton,
  Director
• Sara M. Nayeem,
  Director
• David M Mott,
  Director
• Inc Pfizer Ventures (Us) Ll...,
  
• Enterprise Associates 14, L...,
  
• Michael Gray,
  CFO & COO
• Kenneth Attie,
  SVP, CMO
• Laura A Williams,
  Director
• Carl Goldfischer,
  Director
• Mark Chin,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Braden Michael Leonard,
  10% owner
• Enterprise Associates 14, L...,
  
• Enterprise Associates 14, L...,
  
• Enterprise Associates 14, L...,
  
• Capital Lp Commodore,
  10% owner